Phibro Animal Health Corporation has published the transcript of its First Quarter 2026 Earnings Call, held on November 6, 2025. The event focused on the company's financial performance for the quarter ending September 30, 2025, and included updated financial guidance for the fiscal year ending June 30, 2026. The call was attended by key executives including the Chief Executive Officer, the Chief Financial Officer, the Chief Operating Officer, and the Executive Vice President of Corporate Strategy. Analysts from major financial institutions such as JPMorgan Chase, Morgan Stanley, BNP Paribas, and Bank of America also participated in the call. During the discussion, management highlighted Phibro's expanding geographic presence, particularly following the recent acquisition of the MFA business. "Our market reach had complementary for expansion even went -- was complemented and got stronger with recent acquisition of the MFA business, particularly giving us a stronger base in Asia and in China, Western Europe, Middle East as well as the U.S. beef and swine sectors," said the Chief Executive Officer. The company emphasized its ability to provide customized animal health solutions and a diverse product portfolio, including MFAs, nutrition specialties, and vaccines, with a strong on-farm service team. The full transcript can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phibro Animal Health Corporation published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.
Comments